MedTrace Logo

Repurposing Lithium for Parkinson's Disease: a RCT

NCT06339034 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2025-07-08

No results posted yet for this study

Summary

This study will examine the effects of lithium 20mg/day compared to placebo on MRI and blood-based biomarkers among 20 early-stage Parkinson's disease patients.

Conditions

  • Parkinson Disease

Interventions

DIETARY_SUPPLEMENT

Lithium

5mg of elemental lithium/capsule

OTHER

Placebo

Cellulose-filled capsules

Sponsors & Collaborators

  • Cure Parkinson's

    collaborator OTHER

  • State University of New York at Buffalo

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-07-03
Primary Completion
2025-12-31
Completion
2026-02-28

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06339034 on ClinicalTrials.gov